Evicenter
MarkdownMedical informationP&T meetings
Descartes-08

Generalized myasthenia gravis

Launch
Not announced
Last updated
177 sources

Section 3 of 6

Product information and disease description

302 evidence topics · 138 sources

Product description

Phase of product development

Summary: development and regulatory status
  • Regulatory status: The company states that it has no products approved for sale and has not generated any product sales. The FDA designated Descartes-08 an orphan drug for the treatment of myasthenia gravis on 11/08/2022 (not FDA approved for the orphan indication), and the company announced Regenerative Medicine Advanced Therapy designation for MG on May 22, 2024. A Rare Pediatric Disease Designation for juvenile dermatomyositis (JDM) was granted in September 2024; the company states that approval in JDM may qualify it for a priority review voucher.
  • Special Protocol Assessment: On January 27, 2025, the company announced written agreement from the FDA under the Special Protocol Assessment process on the overall design of the phase 3 AURORA trial, which the company states the FDA determined acceptable to support a future biologics license application (BLA) in MG, subject to the outcome of the trial.
  • Earlier development: The company has completed a phase 1/2 trial in MG with phase 1b, phase 2a, and phase 2b portions; phase 2a results were published in the Lancet Neurology in July 2023, phase 2b results were presented in December 2024, and 12-month data were reported in April 2025 and published in Nature Medicine in January 2026. As of December 31, 2025, Descartes-08 had been administered to over 100 patients with MG, multiple myeloma, and other diseases.
  • AURORA status: The first participant was enrolled in May 2025 (registry actual study start 2025-05-06). The company describes approximately 100 participants with AChR antibody-positive MG; the registry record last updated 2026-09-01 lists actual enrollment of 128, a status of active, not recruiting, estimated primary completion on 2026-12-30, and estimated study completion on 2027-09-30. The company expects topline data in the first quarter of 2027 and plans a BLA filing in mid-2027, and states that it has expanded its medical affairs and commercial teams for launch readiness.
  • Financing: Cash, cash equivalents, and restricted cash were $124.7 million as of September 30, 2026, including the initial $50 million tranche of non-dilutive financing from K2 HealthVentures and $22.8 million raised year to date through the at-the-market program; the company expects these resources to support planned operations, including completion of AURORA, into 2028. The term loan facility provides up to $150.0 million in four tranches, of which $50.0 million had been borrowed as of September 30, 2026, and requires a minimum trailing three-month net product revenue of $40.0 million beginning on January 1, 2029. The accumulated deficit was $857.3 million, and approximately $75.5 million remained available under the at-the-market program. In its full year 2025 results (2026), the company had projected that $126.9 million as of December 31, 2025, would support operations into mid-2027.
  • Other indications: The phase 2 TRITON trial in moderate to severe multi-refractory dermatomyositis and antisynthetase syndrome and the phase 1/2 HELIOS trial in children and young adults with autoimmune diseases, including JDM, are ongoing, with data from both expected in the first half of 2027. After topline data from a phase 2 trial in systemic lupus erythematosus in November 2025, the company decided to no longer pursue development in that indication.
Launch

No evidence found.

Orphan Drug Designation for myasthenia gravis: designated November 2022

Product information

Generic, brand name and therapeutic class of product
Nonproprietary name and code name in the NCI Drug Dictionary
Dosage forms and strengths
Average sales price and wholesale acquisition cost

Not applicable.

American hospital formulary service (AHFS), or other drug classification
NCI Thesaurus classification
Indication
Pharmacology
Mechanism of action
Pharmacodynamics
Pharmacokinetics
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions

Not applicable.

Special populations
Drug/Drug, drug/disease interactions
Effects of other drugs on Descartes-08
Effects of Descartes-08 on other drugs
Dosing and administration
Dosage
Administration
Access and distribution
Co-prescribed/Concomitant therapies
Effect of Descartes-08 on quality measures
Product-specific effect on quality measures

No evidence found.

Product comparison
Descartes-08: mechanism, route, dosing schedule, and approval status

Place of product in therapy

Disease description

Definition and etiology
Definition: autoantibody-mediated disorder of neuromuscular transmission
Epidemiology
Incidence of Generalized myasthenia gravis
Prevalence of Generalized myasthenia gravis
Natural history, survival, and mortality
Mortality and survival: United States Medicare beneficiaries aged 65 years and older
Pathophysiology
AChR antibodies: complement fixation, antigenic modulation, and receptor blockade
Diagnosis
Clinical presentation - signs and symptoms
Long-term morbidity
Myasthenic crisis: frequency, triggers, and outcomes
Glucocorticoid toxicity: United States commercially insured adults with generalized myasthenia gravis

“Among 8833 patients with gMG, 5076 (57.5%) had no GC use and 3757 (42.5%) had any GC use (≥5 mg/d: 1537 [40.9%]; ≥10 mg/d: 860 [22.9%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“During the study period, incident GC toxicities were more common among patients in the any GC use cohort than the no GC use cohort (61.9% vs 52.3% with ≥1 toxicity), with a trend of increasing incidence with increasing GC use (≥5 mg/d: 62.9%; ≥10 mg/d: 67.3%; all P < .001” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Additionally, a greater proportion of patients with any GC use than no GC use had ≥3 incident GC toxicities (16.5% vs 9.5%), with this proportion rising with mean PEDD ≥5 mg (18.9%) and mean PEDD ≥10 mg (22.8%; all P <.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Both acute and chronic incident GC toxicities were more common in the any GC use cohort than the no GC use cohort (acute: 28.5% vs 19.1%; chronic: 51.9% vs 43.8%; both P <.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Since claims data do not contain reasons for diagnoses, toxicities could not be confirmed to be related to GC use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Burden of Generalized myasthenia gravis
Humanistic burden and health-related quality of life
Economic burden and healthcare resource utilization
Range of direct and indirect costs across studies: systematic reviews
Economic impact of Generalized myasthenia gravis on families
Economic impact of diagnostic testing

Approaches to treatment

Current treatment options and standard of care
Acetylcholinesterase inhibitors
Corticosteroids
Nonsteroidal immunosuppressive agents
Indications for and choice of nonsteroidal immunosuppressive agents: international consensus guidance

“A nonsteroidal IS agent should be used alone when corticosteroids are contraindicated or refused. A nonsteroidal IS agent should be used initially in conjunction with corticosteroids when the risk of steroid side effects is high based on medical comorbidities. A nonsteroidal IS agent should be added to corticosteroids when: a. Steroid side effects, deemed significant by the patient or the treating physician, develop; b. Response to an adequate trial (table e-1) of corticosteroids is inadequate; or c. The corticosteroid dose cannot be reduced due to symptom relapse.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Nonsteroidal IS agents that can be used in MG include azathioprine, cyclosporine, mycophenolate mofetil, methotrexate, and tacrolimus. The following factors should be considered in selecting among these agents: a. There is widespread variation in practice with respect to choice of IS agent since there is little literature comparing them. b. Expert consensus and some RCT evidence support the use of azathioprine as a first-line IS agent in MG. c. Evidence from RCTs supports the use of cyclosporine in MG, but potential serious adverse effects and drug interactions limit its use. d. Although available RCT evidence does not support the use of mycophenolate and tacrolimus in MG, both are widely used, and one or both are recommended in several national MG treatment guidelines” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For nonsteroidal IS agents, once treatment goals have been achieved and maintained for 6 months to 2 years, the IS dose should be tapered slowly to the minimal effective amount.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Thymectomy
Intravenous immunoglobulin and plasma exchange
Complement c5 inhibitors
Eculizumab: REGAIN phase 3 trial in refractory AChR antibody-positive disease, 26 weeks

“Eligible patients were aged at least 18 years, with a Myasthenia Gravis-Activities of Daily Living (MG-ADL) score of 6 or more, Myasthenia Gravis Foundation of America (MGFA) class II-IV disease, vaccination against Neisseria meningitides, and previous treatment with at least two immunosuppressive therapies or one immunosuppressive therapy and chronic intravenous immunoglobulin or plasma exchange for 12 months without symptom control.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Between April 30, 2014, and Feb 19, 2016, we randomly assigned and treated 125 patients, 62 with eculizumab and 63 with placebo. The primary analysis showed no significant difference between eculizumab and placebo (least-squares mean rank 56·6 [SEM 4·5] vs 68·3 [4·5]; rank-based treatment difference -11·7, 95% CI -24·3 to 0·96; p=0·0698).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Myasthenia gravis exacerbations were reported by six (10%) patients in the eculizumab group and 15 (24%) in the placebo group. Six (10%) patients in the eculizumab group and 12 (19%) in the placebo group required rescue therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The use of a worst-rank analytical approach proved to be an important limitation of this study since the secondary and sensitivity analyses results were inconsistent with the primary endpoint result; further research into the role of complement is needed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Neonatal fc receptor blockers
B-cell depleting antibodies
Limitations of current therapies
Summary
  • Refractory disease: Refractory MG has been defined as a post-intervention status unchanged or worse after corticosteroids and at least 2 other immunosuppressive agents used in adequate doses for an adequate duration, with persistent symptoms or side effects that limit functioning. An estimated 10% to 20% of patients continue to have long-standing moderate or severe weakness after treatment with at least two different immunosuppressive drugs at high doses, and about 20,000 patients with generalized MG are estimated to be intolerant of or to have an inadequate response to conventional treatment.
  • Incomplete response to targeted biologics: Upward of thirty percent of patients do not benefit from complement inhibition. No head-to-head prospective studies have compared the novel therapies; in one analysis, FcRn inhibitors carried greater odds of treatment-related adverse events than placebo (odds ratio 2.20 [1.52-3.38]), while C5 inhibitors and CD19+ B-cell depletion showed odds comparable to placebo.
  • Glucocorticoid toxicity: Incident glucocorticoid toxicities occurred in 61.9% of patients with any glucocorticoid use and 52.3% of those without; common acute toxicities included nausea and vomiting, pneumonia, fungal infections, sepsis, and urinary tract infection, and chronic toxicities included dyslipidemia, sleep disturbances, obesity, cardiac arrhythmias, and hypertension. Toxicities and costs tended to increase with increasing glucocorticoid use.
  • Infection risk and REMS: Eculizumab, a complement inhibitor, increases the risk of serious infections caused by Neisseria meningitidis, meningococcal vaccination is required at least 2 weeks before the first dose of eculizumab, and eculizumab and zilucoplan are available only through restricted REMS programs. One case of meningococcal meningitis occurred despite vaccination in the eculizumab open-label extension. In Study 1 of efgartigimod, urinary tract infections occurred in 10% of efgartigimod-treated and 5% of placebo-treated patients, and respiratory tract infections in 33% and 29%.
  • Administration burden: Reported limitations include the need for meningococcal vaccination and regular intravenous or subcutaneous injections; eculizumab is infused intravenously over 35 minutes in adults, and the safety of starting rozanolixizumab cycles sooner than 63 days after the start of the previous cycle has not been established. Current targeted therapies generally require lifelong repeated administration and “rarely induce durable treatment-free remission”.
  • Cost: In one cost-effectiveness analysis, eculizumab at an estimated annual cost of $653,100 had an incremental cost-effectiveness ratio of $5,210,000 per QALY/evLYG, and efgartigimod at a placeholder price of $418,400 had $2,076,000 per QALY/evLYG. Very high drug costs have limited access to complement and FcRn inhibitors in most countries. Annual all-cause costs were $76,381 among patients with any glucocorticoid use and $35,309 among those without.
Meningococcal infection risk, vaccination, and REMS with complement C5 inhibitors
Place in treatment, anticipated use, and care setting
Summary
  • Guideline positioning of targeted biologics: Guidance states that clinicians should seek to initiate available targeted therapies in patients with gMG who have active symptoms and for whom conventional therapy does not achieve symptom control within 6 to 12 months or results in excessive treatment-related burden, with use as initial treatment driven by clinician judgment. Complement and FcRn inhibitors are recommended as second- or third-line treatment in severe MG exacerbations and crisis, and their roles are being established especially in patients unresponsive to conventional therapy. Expert recommendations state that an interclass switch should be considered for inefficacy, intolerable side effects, or patient preferences regarding type and frequency of administration, and that a switch to IVIg interval therapy should be considered when targeted immunotherapies fail.
  • Intended population and setting for Descartes-08: The phase 3 AURORA trial enrolls adults with acetylcholine receptor autoantibody-positive generalized MG and administers six once-weekly outpatient infusions without preconditioning chemotherapy. The company states that the current standard of care consists of chronic steroids and other immunosuppressants and that complement and FcRn inhibitors are typically administered continually, estimates that MG affects over 106,000 patients in the U.S., and describes Descartes-08 as the only CAR-T in autoimmune disease it is aware of that is designed for outpatient administration without preconditioning chemotherapy. The company states that conventional DNA cell therapies are administered under close monitoring in an inpatient setting. Investigators of an earlier Descartes-08 study reported the feasibility of preparing the cells for patients on immunosuppressive therapy, using them without lymphodepletion chemotherapy, and administering them in the outpatient setting with minimal post-infusion monitoring, and a later publication describes a “biologic-like approach that involves an initial leukapheresis”. An investigator quoted by the company described outpatient retreatment without lymphodepleting chemotherapy as a potential option for patients who have cycled through multiple therapies.
  • Recommendations on cellular therapy: EBMT recommendations state that cellular therapy in autoimmune diseases should be performed within a clinical trial whenever possible, at expert centres with JACIE accreditation for immune effector cell administration, that the need for and dose of lymphodepletion are not established, and that repeated dosing of BCMA CAR-T has been efficacious in MG without lymphodepletion. A 2026 article on CAR-T therapy in autoimmune disease states that current neurological evidence is limited to small early-phase studies and case reports, with one placebo-controlled trial (generalised MG), and that CAR-T therapy should be considered experimental and delivered in specialised centres.
  • Other CAR-T approaches in MG: In a study of anti-BCMA/CD19 bispecific CAR-T cells given as a single infusion after fludarabine and cyclophosphamide lymphodepletion, 18 participants were enrolled; grade 1 cytokine release syndrome occurred in 39%, and among 17 who completed follow-up, MG-ADL improved by −8.6 (95% CI −10.2 to −7.0) and QMG by −15.4 (−17.6 to −13.2) by day 180, and 14 (82%) achieved minimal manifestations. Three patients with treatment-resistant MG treated with anti-CD19 CAR-T cells (KYV-101) after cyclophosphamide and fludarabine lymphodepletion achieved sustained remission for at least 19 months, and BCMA-directed CAR-T cells in two patients (one AChR-IgG, one MuSK-IgG) produced clinical improvement over 18 months. KYV-101 is being compared with standard-of-care immunosuppressive therapy in the phase 2/3 KYSA-6 study, and CABA-201 is being evaluated with cyclophosphamide and fludarabine and, at escalating doses, without that preconditioning.
  • REMS change for approved CAR-T therapies: The FDA eliminated the REMS for currently approved BCMA- and CD19-directed autologous CAR T cell immunotherapies, removing the requirements for specially certified dispensing sites with on-site, immediate access to tocilizumab. Labeling now calls for monitoring for at least two weeks, including daily monitoring for at least one week, remaining near a healthcare facility for at least two weeks, and avoiding driving for two weeks. In 58 patients with myeloma, lymphoma, or acute lymphoblastic leukemia who received CAR T-cell infusion as outpatients and were seen daily for the first 7 to 10 days, 17 (41%), 16 (38%), and 9 (21%) were admitted between days 0 to 3, 4 to 7, and 8 to 30.
Care setting compared with conventional DNA-based CAR-T cell therapy
BCMA/CD19 bispecific CAR T-cell therapy after fludarabine and cyclophosphamide lymphodepletion: single-arm phase 1 trial, 18 participants with refractory gMG

“Participants received lymphodepleting chemotherapy with fludarabine (30 mg/m2/day) and cyclophosphamide (300 mg/m2/day) for three consecutive days (days −5 to −3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Between May 3, 2023, and June 19, 2024, 18 patients were enrolled and received apheresis and a single CAR T cell infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The anti-BCMA/CD19 bispecific CAR T cells were generally safe, with no dose-limiting toxicities, no immune effector cell-associated neurotoxicity syndrome, and only grade 1 cytokine release syndrome (39% of patients). The most common grade 3 or worse adverse events within 28 days were hematological toxicities, including three leukopenia, three neutropenia, one anaemia, and one thrombocytopenia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“17 participants completed follow-up. Clinical improvements by day 180 were −8.6 (95% CI −10.2 to −7.0) for MG-ADL score and −15.4 (−17.6 to −13.2) for QMG score. 14 participants (82%) achieved minimal manifestations, 15 (88%) stopped glucocorticoids, all stopped non-steroidal immunosuppressants, and eight (47%) had anti-acetylcholine receptor antibody negative seroconversion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

FDA elimination of REMS for approved autologous CAR T-cell therapies, June 2025
Heterogeneity of treatment effect
Descartes-08: AChR antibody-positive subgroup, MGC response at month 3, mITT population (phase 2b)
Descartes-08: biologic-naive versus biologic-exposed participants, post hoc analysis, mITT population (phase 2b)

“A post hoc analysis was conducted to evaluate the magnitude of response to Descartes-08 in participants who were biologic-naive and those with prior biologic exposure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Participants with no prior exposure to complement inhibitors, FcRn inhibitors or CD19/CD20-targeting monoclonal antibodies (biologic-naive) demonstrated an improved response to Descartes-08 compared to those with prior biologic exposure, with 55.6% (n = 5/9) of participants achieving MSE by month 6, which was maintained through month 12.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Additionally, the biologic-naive group had a greater proportion of MGC responders at month 3 compared to the group with prior biologic exposure (88.9% versus 33.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“There were also notable reductions in MG severity scores from baseline to month 3 for the biologic-naive group versus those with prior biologic exposure (mean (s.d.) score: MGC −7.7 (5.24) versus 1.0 (6.96); MG-ADL −5.2 (3.27) versus −2.5 (3.08); QMG −5.0 (3.84) versus −2.2 (4.92)), with scores further improved by month 12 (MGC −11.0 (4.0), MG-ADL −7.1 (1.9), QMG −9.4 (2.6)) (Extended Data Table 5 and Extended Data Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Notably, 100.0% of biologic-naive participants maintained at least a clinically meaningful response at month 12.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Biologic-exposed participants were non-responders to prior FcRn or complement inhibitor treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Among biologic-naive patients, 55.60% achieved MSE by month 6, which was maintained through month 12 without additional treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Inebilizumab effect by antibody status
Week 26 outcomeOverall populationAnti-AChR antibody positiveAnti-MuSK antibody positive
MG-ADL difference from placebo“-1.9”“-1.8”“-2.2”
MG-ADL p-value“<0.0001”“0.0015”“0.0297”
QMG difference from placebo“-2.5”“-2.5”“-2.3”
QMG p-value“0.0002”“0.0011”“NS”
Care management intervention strategies
Washout of MG-relevant immunotherapies before leukapheresis: EBMT recommendations
Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.

Expected outcomes of therapy
Summary
  • Clinically meaningful change: A 2-point improvement in the MG-ADL best predicted clinical improvement (correlation with physician impression of change r = 0.70), and anchor-based and distribution-based minimal clinically important difference cut-offs for the QMG were below a change of 3.0.
  • Treatment goals: Guidance states that the ongoing goal is to achieve and sustain minimal symptoms and treatment-related adverse events with a patient-acceptable quality of life, and to reassess treatment when these cannot be sustained. A consensus definition of adequately controlled gMG requires an MGFA post-intervention status of clinical stable remission, pharmacologic remission, or minimal manifestations stable for a year, an MG-ADL score of 2 or less, no exacerbation in the last year requiring a change in immunosuppressive or rescue therapy, and no or mild adverse events to therapy.
  • Effect sizes of targeted therapies: An analysis of 27 placebo-controlled randomized trials (placebo n = 1,086; treatment n = 1,232) estimated QMG reductions beyond placebo and standard of care of -3.63 (95% credible interval -4.43 to -2.77) points for FcRn inhibitors, -2.59 (-3.92 to -1.28) for C5 complement inhibitors, and -2.50 (-5.11 to 0.12) for CD19+ B-cell depletion, and MG-ADL effects of -1.93 (-2.21 to -1.65), -1.84 (-2.48 to -1.19), and -1.91 (-2.97 to -0.84); meaningful differences between classes were not observed. In an Argenx-funded study, intravenous efgartigimod had the lowest number needed to treat versus placebo for 3-point and 5-point QMG reductions and a 5-point MG-ADL reduction, rozanolixizumab had the lowest for a 3-point MG-ADL reduction, and the number needed to harm was similar across treatments. With eculizumab, minimal symptom expression on the MG-ADL was reached by 21.4% of patients versus 1.7% with placebo at REGAIN week 26, and by 22.9% and 27.8% of the eculizumab/eculizumab and placebo/eculizumab groups at extension week 130.
  • Company expectations for Descartes-08: The company states that Descartes-08 is being developed with the goal of providing “sustained clinical benefit following a finite course of treatment”, that sustained benefits were observed through 12 months in the phase 2b trial, and that it believes a single course has the potential to transform the MG treatment paradigm. The company states that its cell therapies are designed to be dosed repeatedly like conventional drugs, in an outpatient setting and without pre-treatment chemotherapy, that retreatment is possible if symptoms return, and that achievement of minimal symptom expression over time remains a key treatment goal for physicians.
Expected effect sizes of FcRn inhibitors, C5 inhibitors, and CD19 B-cell depletion on MG-ADL and QMG: 27 placebo-controlled randomized trials